Tepotinib-induced interstitial lung disease in a patient with adenosquamous lung carcinoma

Takeshi Imakura(Tokushima Prefectural Central Hospital), Takashi Haku(Tokushima Prefectural Central Hospital), Hitomi Kagawa(Tokushima Prefectural Central Hospital), Soji Kakiuchi(Tokushima Prefectural Central Hospital), Hiroki Yamamoto(Tokushima Prefectural Central Hospital), Ikumi Nishimura(Tokushima Prefectural Central Hospital), Naoya Murakami(Tokushima Prefectural Central Hospital), Mami Inayama(Tokushima University)
Respiratory Medicine Case Reports
December 30, 2025
10.1016/j.rmcr.2025.102355
Cited by 1

Related Papers

Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations
|Cancer Research|2008|642
Expression profiles of non-small cell lung cancers on cDNA microarrays: Identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs
|Oncogene|2003|324
Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839)
|Human Molecular Genetics|2004|175
Genome-wide analysis of organ-preferential metastasis of human small cell lung cancer in mice.
|PubMed|2003|114
Retreatment of Lung Adenocarcinoma Patients With Gefitinib Who Had Experienced Favorable Results From Their Initial Treatment With This Selective Epidermal Growth Factor Receptor Inhibitor: A Report of Three Cases
|Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics|2005|97